Being a NASDAQ-listed clean energy company is both an opportunity and a challenge, especially with limited resources in a capital-intensive industry. But we remain focused on execution ...

Source: Nutriband Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the ...

On behalf of Uxin Limited, I would like to express my sincere appreciation for your continued interest and support. It is my pleasure to share with you our key achievements over the past year ...

On behalf of the Board of Directors and the management team at Baozun, I would like to express our deepest appreciation for your continued support and trust — especially during a year marked by ...

Trump Media and Technology Group Corp. is expanding its portfolio with the upcoming launch of Truth.Fi, a financial services and FinTech brand. The company is engaging directly with shareholders ...

Nutriband Inc. has issued a letter to shareholders from CEO Gareth Sheridan, outlining the company's accomplishments in 2024 and discussing future prospects for 2025. The company is progressing ...

Despite the unsettling geopolitical discord, we are pleased with our progress since launching the Company, as a Nasdaq listed company, and its unique products of Non-GMO cold-pressed and ...

Tevogen Bio Holdings Inc. announced that CD8 Technology Services LLC has signed a letter of intent to design a facility that will support Tevogen’s cell therapy manufacturing efforts.

L.P. (“Soleus Capital”), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ: THTX) (the “Company”), today sent a letter to the Board of ...

Urges Shareholders to Vote “FOR” ONLY Phillips 66’s Nominees on the WHITE Proxy Card In conjunction with today’s shareholder letter, Phillips 66 published a new video on phillips66delivers ...

which are summarized in the Addendum to this letter. As you know, our shares have been halted from trading on NASDAQ since February 22, 2019. Despite the trading halt, the Company continued to ...

Longeveron announces CEO's letter detailing progress on stem cell therapies for Alzheimer’s disease and Hypoplastic Left Heart Syndrome. Longeveron Inc. has announced progress in its cellular ...